G1 Therapeutics, Inc.

GTHX

US3621LQ1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
3.24 ^USD	+1.57%		+26.07%	+6.23%

07-01	G1 Therapeutics Joins Russell 3000, Russell 2000 Indexes	MT
07-01	G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell Small Cap Completeness Index	CI

G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about G1 Therapeutics, Inc.

G1 Therapeutics Joins Russell 3000, Russell 2000 Indexes	07-01	MT
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell Small Cap Completeness Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2000 Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 3000E Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 3000 Growth Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 3000E Growth Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2000 Growth Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2000 Dynamic Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2500 Growth Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell Small Cap Comp Growth Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 2500 Index	06-30	CI
G1 Therapeutics, Inc.(NasdaqGS:GTHX) added to Russell 3000 Index	06-30	CI
Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating	06-25	MT
HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating	06-25	MT
Top Midday Decliners	06-24	MT
Wedbush Adjusts Price Target on G1 Therapeutics to $3 From $5, Maintains Outperform Rating	06-24	MT
Sector Update: Health Care Stocks Advance Premarket Monday	06-24	MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data	06-24	MT
Transcript : G1 Therapeutics, Inc. - Special Call	06-24
Top Premarket Decliners	06-24	MT
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints	06-24	MT
G1 Therapeutics' breast cancer drug fails in late-stage trial	06-24	RE
G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer	06-24	CI
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024	06-24	CI
TScan Therapeutics, Inc Announces Board and Committee Changes	06-14	CI

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for G1 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.19 USD

Average target price

4.5 USD

Spread / Average Target

+41.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
G1 THERAPEUTICS, INC.	+6.23%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	126B
ARGENX SE	+24.16%	27.95B
BIONTECH SE	-20.17%	20.5B
GENMAB A/S	-16.06%	17.12B
BEIGENE, LTD.	-18.07%	16.1B
WUXI APPTEC CO., LTD.	-47.70%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.38B
INSMED INCORPORATED	+149.98%	12.37B

Bio Therapeutic Drugs